Mixed Features in Depressive EpisodesManaging Patients Across the Disease Spectrum
Mixed specifier for bipolar mania and depression: highlights of DSM-5 changes and implications for diagnosis and treatment in primary care.
Hu J, et al. Prim Care Companion CNS Disord. 2014;16(2).
Zimmermann P, et al. Arch Gen Psychiatry. 2009;66(12):1341-1352.
A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State.
Patkar A, et al. Plos ONE. 2012;7(4):e34757.
The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.
McIntyre RS, et al. J Affect Disord. 2014;12(172C):259-264.
Tohen M, et al. J Affect Disord. 2014;164:57-62.
Perugi G, et al. J Clin Psychiatry. 2015;76(3):e351-e358.
Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS, et al. J Clin Psychiatry. 2015;76(4):398-405.
Managing Patients Across the Disease Spectrum
Improved Diagnostic and Management Strategies
Overcoming Diagnostic Challenges, Targeting Remission, and Optimizing Cardiometabolic Health
New Approaches to Optimizing Patient Outcomes
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Accelerating Diagnosis, Achieving Remission, and Encouraging Adherence
Best Practices for Emergency Care
Consensus and Controversies Across the Spectrum of Patient Presentations
Finding the Way Forward
Updates, Clinical Scenarios, and Future Directions